DUBLIN–(BUSINESS WIRE)–The “Follicular Lymphoma- Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
The “Follicular Lymphoma – Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Follicular Lymphoma Emerging Drugs Chapters
This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular Lymphoma Emerging Drugs
Mosunetuzumab – Genentech
Mosunetuzumab (Anti-CD20 x CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cell. Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format).The drug is currently in phase 3 stage of development for the treatment of Follicular Lymphoma.
Tafasitamab – Incyte Corporation
Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Pembrolizumab: Merck & Co
Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body’s own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.
Zanubrutinib – BeiGene
Zanubrutinib (BGB-3111) – a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BTK is a key component of the B-cell receptor, or BCR, signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies. BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignant white blood cells called B-cells. Zanubrutinib is an orally active inhibitor that covalently binds to BTK, resulting in irreversible inactivation of the enzyme.
Follicular Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Follicular Lymphoma
There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genetech.
Key Questions
- How many companies are developing Follicular Lymphoma drugs?
- How many Follicular Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular Lymphoma?
- What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Follicular Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Merck & Co
- Genentech
- Incyte Corporation
- Syndax Pharmaceuticals
- Dr Reddy’s Laboratories
- Novartis
- ADC Therapeutics
- Xynomic Pharmaceuticals
- Cho Pharma Inc.
- Janssen
- XEME Biopharma Inc.
- Shanghai Yingli Pharmaceutical
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd.
- Archigen Biotech
- Hutchison Medipharma Limited
- Nordic Nanovector
- Xynomic Pharmaceuticals
- TG Therapeutics
- BeiGene
- Allogene Therapeutics
- MEI Pharma, Inc.
- Pfizer
- Innovent Biologics (Suzhou) Co. Ltd.
- Enterome
- AstraZeneca
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Takeda
- Bristol-Myers Squibb
- TCR2 Therapeutics
Key Products
- Pembrolizumab
- Mosunetuzumab
- Tafasitamab
- Entinostat
- DRL_RI
- Tisagenlecleucel
- Loncastuximab Tesirine
- Abexinostat
- CHO-H01
- Ibrutinib
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wgzr6n
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900